journal
Journals European Journal of Drug Metab...

European Journal of Drug Metabolism and Pharmacokinetics

https://read.qxmd.com/read/38635015/long-acting-strategies-for-antibody-drugs-structural-modification-controlling-release-and-changing-the-administration-route
#1
REVIEW
Hao Wang, Mengdi Song, Jiaqi Xu, Zhenjing Liu, Mingyue Peng, Haoqiang Qin, Shaoqian Wang, Ziyang Wang, Kehai Liu
Because of their high specificity, high affinity, and targeting, antibody drugs have been widely used in the treatment of many diseases and have become the most favored new drugs for research in the world. However, some antibody drugs (such as small-molecule antibody fragments) have a short half-life and need to be administered frequently, and are often associated with injection-site reactions and local toxicities during use. Increasing attention has been paid to the development of antibody drugs that are long-acting and have fewer side effects...
April 18, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38564097/a-phase-i-clinical-study-comparing-the-pharmacokinetics-safety-and-immunogenicity-of-gb221-injection-and-trastuzumab-herceptin-%C3%A2-in-healthy-chinese-adults
#2
JOURNAL ARTICLE
Yu Zhu, Chen Li, Liming Chen, Haiyan Liu, Lun Ou, Tong Li, Xuan Wang, Tenghua Wang, Jingyuan Tian, Xintong Liang, Zhiqin Hu, Yaoxuan Zhan, Shuangshuang Xiao, Xiaole Wang, Yongmei Li, Jin He, Qingshan Zheng, Haifeng Song, Xianbo Li, Yi Fang
BACKGROUND AND OBJECTIVE: GB221 is a recombinant humanized anti-HER2 monoclonal antibody. The purpose of this study was to evaluate the pharmacokinetic, safety, and immunogenicity of GB221 in healthy Chinese adults in comparison to trastuzumab (Herceptin® ). METHODS: In this randomized, double-blind, parallel-group phase I clinical trial, 88 subjects were randomized 1:1 to receive a single intravenous infusion (90-100 min) of GB221 or trastuzumab (6 mg/kg)...
April 2, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38554232/assessment-of-the-effects-of-abrocitinib-on-the-pharmacokinetics-of-probe-substrates-of-cytochrome-p450-1a2-2b6-and-2c19-enzymes-and-hormonal-oral-contraceptives-in-healthy-individuals
#3
JOURNAL ARTICLE
Xiaoxing Wang, Martin E Dowty, Sakambari Tripathy, Vu H Le, Yeamin Huh, Madelyn Curto, Jennifer A Winton, Melissa T O'Gorman, Gary Chan, Bimal K Malhotra
BACKGROUND AND OBJECTIVE: Abrocitinib is an oral small-molecule Janus kinase (JAK)-1 inhibitor approved for the treatment of moderate-to-severe atopic dermatitis. In vitro studies indicated that abrocitinib is a weak time-dependent inhibitor of cytochrome P450 (CYP) 2C19/3A and a weak inducer of CYP1A2/2B6/2C19/3A. To assess the potential effect of abrocitinib on concomitant medications, drug-drug interaction (DDI) studies were conducted for abrocitinib with sensitive probe substrates of these CYP enzymes...
March 30, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38521893/a-phase-i-open-label-mass-balance-study-of-14-c-iberdomide-in-healthy-subjects
#4
JOURNAL ARTICLE
Yiming Cheng, Xiaomin Wang, Liangang Liu, Jose Silva, Michael Thomas, Yan Li
BACKGROUND: Iberdomide is a novel potent cereblon modulator (CELMoD® ) agent, which is currently under clinical development for hematological malignancies. A human mass balance study was conducted to characterize the biotransformation and excretion pathways of iberdomide. METHOD: After a single dose of radiolabelled [14 C]-iberdomide (1 mg) in six healthy subjects. Blood, urine, and fecal samples were collected for pharmacokinetics, mass balance, and clinical laboratory assessments...
March 23, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38494536/correction-population-pharmacokinetic-analysis-of-vancomycin-in-patients-with-solid-or-hematological-malignancy-in-relation-to-the-quick-sequential-organ-failure-assessment-scores
#5
Yasumasa Tsuda, Masahiro Takahashi, Fumiya Watanabe, Kazumi Goto, Hirotoshi Echizen
No abstract text is available yet for this article.
March 18, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38472634/kinetic-characterization-of-estradiol-glucuronidation-by-liver-microsomes-and-expressed-ugt-enzymes-the-effects-of-organic-solvents
#6
JOURNAL ARTICLE
Caimei Wu, Meixue Luo, Dihao Xie, Simin Zhong, Jiahao Xu, Danyi Lu
BACKGROUND AND OBJECTIVE: In vitro glucuronidation of 17β-estradiol (estradiol) is often performed to assess the role of uridine 5'-diphospho-glucuronosyltransferase 1A1 (UGT1A1) in xenobiotic/drug metabolism. The objective of this study was to determine the effects of four commonly used organic solvents [i.e., dimethyl sulfoxide (DMSO), methanol, ethanol, and acetonitrile] on the glucuronidation kinetics of estradiol, which can be glucuronidated at C3 and C17 positions. METHODS: The impacts of organic solvents on estradiol glucuronidation were determined by using expressed UGT enzymes and liver microsomes from both human and animals...
March 12, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38461486/anti-calcitonin-gene-related-peptide-monoclonal-antibodies-in-migraine-focus-on-clinical-pharmacokinetics
#7
REVIEW
Slobodan M Janković, Snežana V Janković
The calcitonin gene-related peptide transmission was the target for recent development of drugs that effectively prevent attacks of both episodic and chronic migraine. The aim of this narrative review was to offer deeper insight into pharmacokinetics of monoclonal antibodies approved for prevention of migraine attacks. For this narrative review, relevant literature was searched for in MEDLINE and Google Scholar databases, covering periods 1966-2023 and 2006-2023, respectively. The ClinicalTrials.gov database was also searched for relevant clinical studies whose results had not been published previously in medical journals, covering the period 2000-2023...
March 10, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38457093/anti-calcitonin-gene-related-peptide-monoclonal-antibodies-in-migraine-focus-on-drug-interactions
#8
REVIEW
Slobodan M Janković, Snežana V Janković
Calcitonin gene-related peptide neurotransmission was the target for recent development of monoclonal antibodies that effectively prevent attacks of both episodic and chronic migraine. The aim of this narrative review was to offer deeper insight into drug-drug, drug-food and drug-disease interactions of monoclonal antibodies approved for prevention of migraine attacks. For this narrative review, relevant literature was searched for in MEDLINE and Google Scholar databases, covering the 1966-2023 and 2006-2023 periods, respectively...
March 8, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38457092/predicting-pharmacokinetics-of-drugs-using-artificial-intelligence-tools-a-systematic-review
#9
Mahnaz Ahmadi, Bahareh Alizadeh, Seyed Mohammad Ayyoubzadeh, Mahdiye Abiyarghamsari
BACKGROUND AND OBJECTIVE: Pharmacokinetic studies encompass the examination of the absorption, distribution, metabolism, and excretion of bioactive compounds. The pharmacokinetics of drugs exert a substantial influence on their efficacy and safety. Consequently, the investigation of pharmacokinetics holds great importance. However, laboratory-based assessment necessitates the use of numerous animals, various materials, and significant time. To mitigate these challenges, alternative methods such as artificial intelligence have emerged as a promising approach...
March 8, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38446388/safety-tolerability-and-pharmacokinetics-of-the-monoamine-oxidase-b-inhibitor-hec122505-and-its-major-metabolite-after-single-and%C3%A2-multiple-ascending-dose-and-food-effect-study-in-healthy-chinese-subjects
#10
JOURNAL ARTICLE
Chuanfei Jin, Chao Yi, Kangzhi Chen, Haiping Liang
BACKGROUND AND OBJECTIVES: HEC122505 is a potent and selectively monoamine oxidase B inhibitor that is safe and well-tolerated in preclinical models of Parkinson's disease. The objectives of single ascending dose and multiple dose pharmacokinetic trials of HEC122505 oral tablets were to determine the safety and tolerability of HEC122505, and to examine the food effect on the pharmacokinetic parameters of HEC122505 and its major metabolite HEC129870. METHODS: The phase I study (NCT04625361) consisted of three arms: single ascending dose study (5, 20, 50, 100, 200, 300 or 400 mg HEC122505 tablets or placebo), multiple ascending dose study (20, 50 or 100 mg HEC122505 tablets or placebo once daily), and food effect (100 mg HEC122505 tablets single dose after a high-fat, high-calorie meal)...
March 6, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38393637/pharmacokinetic-study-of-ultrasmall-superparamagnetic-iron-oxide-nanoparticles-hy-088-in-rats
#11
JOURNAL ARTICLE
Xin Song, Minglan Zheng, Heping Hu, Lei Chen, Shuzhe Wang, Zhao Ding, Guangyi Fu, Luyao Sun, Liyuan Zhao, Ling Zhang, Bohua Xu, Yunliang Qiu
BACKGROUND AND OBJECTIVE: HY-088 injection is an ultrasmall superparamagnetic iron oxide nanoparticle (USPIOs) composed of iron oxide crystals coated with polyacrylic acid (PAA) on the surface. The purpose of this study was to investigate the pharmacokinetics, tissue distribution, and mass balance of HY-088 injection. METHODS: The pharmacokinetics of [55 Fe]-HY-088 and [14 C]-HY-088 were investigated in 48 SD rats by intravenous injection of 8.5 (low-dose group), 25...
February 23, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38381348/pharmacokinetics-safety-profile-and-tolerability-of-tetramethylpyrazine-nitrone-tablets-after-single-and-multiple-ascending-doses-in-healthy-chinese-volunteers
#12
JOURNAL ARTICLE
Gangzhi Zhu, Liu Wang, Shaojin Zhong, Shengnan Han, Hui Peng, Mei Tong, Xiaoai He
BACKGROUND AND OBJECTIVES: Tetramethylpyrazine nitrone (TBN) is a novel tetramethylpyrazine derivative armed with a strong free radical scavenging nitrone moiety. This study aims to evaluate the pharmacokinetics, safety profile, and tolerability of TBN tablets after a single ascending dose (SAD) and multiple ascending doses (MAD) in healthy Chinese volunteers. METHODS: This phase I, single-center, open-label study was conducted in China. The SAD portion consisted of four cohorts with dose levels of 400-1800 mg...
February 21, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38376657/pharmacokinetics-of-dasatinib-in-rats-a-potential-food-drug-interaction-with-naringenin
#13
JOURNAL ARTICLE
Mohammad Raish, Ajaz Ahmad, Badr Abdul Karim, Yousef A Bin Jardan, Abdul Ahad, Muzaffar Iqbal, Khalid M Alkharfy, Fahad I Al-Jenoobi, Omer Mansour Mohammed
BACKGROUND AND OBJECTIVES: The novel tyrosine kinase inhibitor (TKI) dasatinib, a multitarget inhibitor of Bcr-Abl and Src family kinases, has been licensed for the treatment of Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia. Many citrus-based foods include the flavonoid naringenin, which is commonly available. Dasatinib is a Cyp3a4, P-gp, and Bcrp1 substrate, which makes it sensitive to potential food-drug interactions. The concurrent use of naringenin may change the pharmacokinetics of dasatinib, which could result in adverse effects and toxicity...
February 20, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38367175/pharmacokinetic-pharmacodynamic-modelling-in-hemophilia-a-relating-thrombin-and-plasmin-generation-to-factor-viii-activity-after-administration-of-a-vwf-fviii-concentrate
#14
JOURNAL ARTICLE
Lars L F G Valke, Michael E Cloesmeijer, Hassan Mansouritorghabeh, Wideke Barteling, Nicole M A Blijlevens, Marjon H Cnossen, Ron A A Mathôt, Saskia E M Schols, Waander L van Heerde
BACKGROUND: Hemophilia A patients are treated with factor (F) VIII prophylactically to prevent bleeding. In general, dosage and frequency are based on pharmacokinetic measurements. Ideally, an alternative dose adjustment can be based on the hemostatic potential, measured with a thrombin generation assay (TGA), like the Nijmegen hemostasis assay. OBJECTIVE: The objective of this study was to investigate the predicted performance of a previously developed pharmacokinetic-pharmacodynamic model for FVIII replacement therapy, relating FVIII dose and FVIII activity levels with thrombin and plasmin generation parameters...
February 17, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38332426/influence-of-bile-acids-on-clindamycin-hydrochloride-skin-permeability-in%C3%A2-vitro-and-in%C3%A2-silico-preliminary-study
#15
JOURNAL ARTICLE
Dragana Zaklan, Dušan Nešić, Darko Mitrović, Slavica Lazarević, Maja Đanić, Momir Mikov, Nebojša Pavlović
BACKGROUND AND OBJECTIVE: Topical clindamycin formulations are widely used in clinical practice, but poor bioavailability and restricted skin penetration considerably limit their therapeutic efficacy. Penetration enhancement represents a promising and rational strategy to overcome the drawbacks of conventional topical pharmaceutical formulations. We aim to assess the influence of cholic acid (CA) and deoxycholic acid (DCA) on the permeability of clindamycin hydrochloride by performing the in vitro skin parallel artificial membrane permeability assay (skin-PAMPA) at two relevant pH values (5...
February 8, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38332425/optimizing-antibiotic-therapy-for-intravenous-drug-users-a-narrative-review-unraveling-pharmacokinetics-pharmacodynamics-challenges
#16
JOURNAL ARTICLE
Marta Colaneri, Camilla Genovese, Pietro Valsecchi, Matteo Calia, Dario Cattaneo, Andrea Gori, Raffaele Bruno, Elena Seminari
Intravenous drug users (IVDUs) face heightened susceptibility to life-threatening gram-positive bacterial infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). While the standard antibiotic dosing strategies for special patients, such as obese or critically ill individuals, are known to be inadequate, raising concerns about treatment efficacy, a similar sort of understanding has not been assessed for IVDUs yet. With this in mind, this review examines the pharmacokinetic/pharmacodynamic characteristics of antibiotics commonly used against gram-positive bacteria in IVDUs...
February 8, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38329646/pharmacokinetics-of%C3%A2-the%C3%A2-novel-nonsteroidal-mineralocorticoid-receptor-antagonist-ocedurenone-kbp-5074-in%C3%A2-individuals-with%C3%A2-moderate-hepatic-impairment
#17
JOURNAL ARTICLE
James McCabe, Jay Zhang, Fred Yang, Vincent Benn
BACKGROUND AND OBJECTIVES: Ocedurenone (KBP-5074) is a novel nonsteroidal mineralocorticoid receptor antagonist that has demonstrated safety and efficacy in clinical trials in patients with uncontrolled hypertension and stage 3b/4 chronic kidney disease. The aim of this study was to assess the pharmacokinetics, safety, and tolerability of ocedurenone in individuals with moderate hepatic impairment. METHODS: This study was an open-label, nonrandomized, multi-center study investigating the pharmacokinetics, safety, and tolerability of a single dose of 0...
February 8, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38172422/improved-pharmacokinetic-and-pharmacodynamic-profile-of-deuterium-reinforced-tricyclic-antidepressants-doxepin-dosulepin-and-clomipramine%C3%A2-in-animal-models
#18
JOURNAL ARTICLE
Shreyash Moharir, Likhit Akotkar, Urmila Aswar, Dileep Kumar, Bapu Gawade, Kavita Pal, Rajesh Rane
BACKGROUND AND OBJECTIVES: Doxepin, dosulepin, and clomipramine are tricyclic antidepressants (TCAs) that act as serotonin and noradrenaline reuptake inhibitors. The metabolites formed by N-dealkylation of these tricyclic antidepressants contribute to overall poor pharmacokinetics and efficacy. Deuteration of the methyl groups at metabolically active sites has been reported to be a useful strategy for developing more selective and potent antidepressants. This isotopic deuteration can lead to better bioavailability and overall effectiveness...
January 3, 2024: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38141154/pharmacokinetic-interaction-between-imatinib-and-metformin-in-rats
#19
JOURNAL ARTICLE
Naling Fan, Liying Du, Teng Guo, Mingfeng Liu, Xinran Chen
BACKGROUND AND OBJECTIVE: Imatinib is primarily transported into the liver by organic cation transporter 1 (OCT1), organic anion transporting polypeptide 1B3 (OATP1B3), and novel organic cation transporter 2 (OCTN2), which is the first step in the metabolic and elimination of imatinib. Patients taking imatinib may concurrently take metformin, a substrate for OCT1. Drug-drug interactions (DDI) may occur between imatinib and metformin, affecting the clinical efficacy of imatinib. This experiment aimed to investigate the pharmacokinetic effects of metformin on imatinib and its active metabolism of N-desmethyl imatinib in rats...
December 23, 2023: European Journal of Drug Metabolism and Pharmacokinetics
https://read.qxmd.com/read/38127227/pharmacokinetics-of-long-acting-methylphenidate-formulation-differences-bioequivalence-interchangeability
#20
Mostafa Moharram, Tony Kiang
UNLABELLED: BACKGROUND AND OBJECTIVE: Attention deficit hyperactivity disorder is one of the most common neuropsychiatric conditions in children, and methylphenidate (MPH) is one of the first-line therapies. MPH is available in a variety of extended-release (ER) formulations worldwide, and most formulations are not considered bioequivalent due to differences in pharmacokinetics. It is hypothesized that the current bioequivalence guidelines from the different regulatory bodies may generate inconsistent findings or recommendations when assessing the bioequivalence of ER MPH formulations...
December 21, 2023: European Journal of Drug Metabolism and Pharmacokinetics
journal
journal
26770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.